Clinical Trial Update: A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies [Phase 1]

View source ↗

Summary

Phase I study of temsirolimus (CCI-779) in combination with topotecan for gynecologic cancers; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• Hycamtin (Topotecan)
• Torisel (Temsirolimus)

Snippet

Sponsor: University of Chicago | Conditions: Genital Neoplasms, Female | Phase 1 | Status: COMPLETED